Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathway.

ABSTRACT:

Background

Atherosclerosis is a chronic disease, with smoking being an independent risk factor. Irisin, a factor produced by myocytes, is expected to treat smoking-related arteriosclerosis, however its specific mechanism remains unclear.

Methods

Forty Apoe-/- mice with nicotine intervention were involved in this study. The atherosclerotic lesions, smooth muscle cell proliferation, and macrophage infiltration induced by nicotine, and the corresponding changes caused by the administration of irisin, were obtained. The integrin αVβ5 inhibitor, cilengitide, was included to determine the cell entry pathway of irisin. Proteins and mRNA levels of phosphatidylinositol 3-kinase (PI3K) and downstreams were detected to clarify the specific molecular mechanism of irisin activity.

SUBMITTER: Li K 

PROVIDER: S-EPMC8246167 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature